scorecardresearch
Add as a preferred source on Google
Saturday, September 19, 2026
Celebrating 9 Years
Support Our Journalism

Support our Journalism

9th Anniversary: Free Tote & Mug

Subscribe
HomeIndiaOdisha-based start-up tests drug manufacturing in near-space mission

Odisha-based start-up tests drug manufacturing in near-space mission

Follow Us :
Text Size:

New Delhi, Aug 14 (PTI) An Odisha-based space start-up successfully demonstrated drug crystallisation processes on a satellite prototype in a near-space mission, taking it a step further towards its goal of pharmaceutical manufacturing in low Earth orbit.

The orbital-class satellite prototype of Serendipity Space tested core technologies, including advanced heatshield systems, avionics and its autonomous pharmaceutical factory, Alchemy, company founder and CEO Antariksh Parichha said in a statement.

“The system operated continuously in harsh space conditions, successfully executing drug crystallisation processes and preserving crystal integrity through a controlled return, touchdown and recovery,” he said.

Parichha drew inspiration from an easier-to-inject version of the cancer drug Keytruda that was developed in the microgravity lab on the International Space Station by Merck in collaboration with NASA.

Serendipity Space’s mission carried commercial monoclonal antibody therapeutics and small molecules, each underpinning multi-billion-dollar markets, alongside additional proteins for drug discovery.

The launch was conducted using a stratospheric balloon launch platform leveraging the decades-long expertise of scientists at the Tata Institute of Fundamental Research (TIFR) Balloon Facility, Hyderabad.

The Bhubaneswar-based start-up is building satellites that can autonomously manufacture pharmaceuticals in space and bring them back to Earth, targeting a critical bottleneck in drug development.

“On Earth, gravity disrupts crystallisation, leading to defects that reduce drug solubility, stability and effectiveness. In microgravity, these constraints disappear, enabling the formation of superior crystal structures without altering the underlying chemistry of the drug,” Parichha said.

He said many existing drugs suffer from poor bioavailability due to suboptimal crystal forms.

In parallel, protein-based therapies like monoclonal antibodies often require long IV infusions because high-concentration formulations become unstable while being made under gravity.

Microgravity can enable uniform, stable formulations that could shift these treatments to simple at-home injections.

Serendipity Space was co-founded by Parichha, Jivitesh Debata and Dr Monica Ekal, combining their expertise in physics, engineering and space operations. PTI SKU DIV DIV

This report is auto-generated from PTI news service. ThePrint holds no responsibility for its content.

Subscribe to our channels on YouTube, Telegram & WhatsApp

Nine Years, Made Possible by Readers

In 2017, Shekhar Gupta started ThePrint with a simple belief: Indian readers want journalism that asks why and what next, not just what. And that enough of them would be willing to pay for good journalism.

Nine years on, that belief has held.

And, in these nine years, we’ve stayed true to our mission. We’ve been asking the follow-up questions, going beyond the headlines and explaining what’s actually happening. We’ve travelled across the country to bring you in-depth, visually-compelling stories from the ground.

It’s been nine years of readers choosing to make this possible. If you’d like to be one of them:

Support ThePrint

  • Tags

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular